Isolated anti-β2-glycoprotein I antibodies in neurology: A frontier syndrome between multiple sclerosis and antiphospholipid syndrome?

European Journal of Neurology

Volumn 21, Issue 6, 2014, Pages 901-906

  Renaud, M ^a   Aupy, J ^a   Uring Lambert, B ^a   Chanson, J B ^a   Collongues, N ^a   Blanc, F ^a   De Seze J ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Anti 2 GPI; Anticardiolipin; Antiphospholipid; Multiple sclerosis; Myelitis; Vasculitis

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1;

ADOLESCENT; ADULT; AGED; ANTIBODY ISOLATION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN ISCHEMIA; BRAIN VASCULITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; MYELITIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; FRANCE; IMMUNOLOGY; MIDDLE AGED; NEUROLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84899948582     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12408     Document Type: Article

References (25)

1. Nimpf J, Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 142-149.
2. Inanc M, Radway-Bright EL, Isenberg DA. β2-glycoprotein I and anti-β2-glycoprotein I antibodies. Where are we now? Br J Rheumatol 1997; 36: 1247-1257.
3. Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181-1182.
4. Brey RL, Abbott RD, Curb JD, et al. Beta(2)-glycoproteinI-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001; 32: 1701-1706.
5. Barned S, Goodman AD, Mattson DH. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology 1995; 45: 384-385.
6. Tourbah A, Clapin A, Gout O, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998; 55: 517-521.
7. Tristano AG. Autoimmune diseases associated with transverse myelitis. Rev Invest Clin 2009; 50: 251-270.
8. Kim JH, Lee SI, Park SI, Yoo WH. Recurrent transverse myelitis in primary antiphospholipid syndrome: case report and literature review. Rheumatol Int 2004; 24: 244-246.
9. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79: 57-68.
10. Lin CH, Kadakia S, Frieri M. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmun Rev 2014; 13: 114-116.
11. Rodrigues CE, de Carvalho JF. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum 2011; 40: 349-357.
12. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42: 200-213.
13. Sherer Y, Hassin S, Shoenfeld Y, et al. Transverse myelitis in patients with antiphospholipid antibodies: the importance of early diagnosis and treatment. Clin Rheumatol 2002; 21: 207-210.
14. Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40: 97-108.
15. Galanaud D, Dormont D, Marsault C, Wechsler B, Piette JC. Brain MRI in patients with past lupus-associated chorea. Stroke 2000; 31: 3079-3083.
16. Marullo S, Clauvel JP, Intrator L, Danon F, Brouet JC, Oksenhendler E. Lupoid sclerosis with antiphospholipid and antimyelin antibodies. J Rheumatol 1993; 20: 747-749.
17. Garcia CO, Kanbour-Shakir A, Tang H, Molina JF, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am J Reprod Immunol 1997; 37: 118-124.
18. Shi W, Chong BH, Hogg PJ, et al. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-345.
19. Matsuura E, Shen L, Matsunami Y, et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus 2010; 19: 379-384.
20. Cuadrado MJ, Khamashta MA. The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects. Bailliere's Best Pract Res Clin Rheumatol 2000; 14: 151-163.
21. Atsumi T, Khamashta MA, Haworth RS, et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998; 41: 800-807.
22. Schulze-Lohoff E, Krapf F, Bleil L, et al. IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome. Rheumatol Int 1989; 9: 43-48.
23. Godeau B, Piette JC. The significance and treatment of antiphospholipid antibodies. Presse Med 2004; 33: 944-952.
24. Tozzoli R, Villalta D. Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev 2014; 13: 59-63.
25. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009; 113: 985-994.